Physician profile
David John Waldstein
NPI 1396748224
$6,631.93
in general payments reported to CMS, 2019-2025
42 companies · $1,736 in 2025
The $1,736 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,000 · 2020: $219 · 2021: $242 · 2022: $956 · 2023: $1,084 · 2024: $1,396 · 2025: $1,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,215.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,076.11 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $686.30 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Pfizer INC. | $534.22 | 2019-2025 | |
| Amgen INC. | $425.44 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $383.10 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $337.86 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.33 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $292.47 | 2022-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $286.85 | 2019-2024 | Camzyos, Eliquis |
| Boston Scientific Corporation | $241.16 | 2022-2025 | Cds - Mct/Cem Monitoring, Watchman Access System, Bodyguardian |
| Novo Nordisk INC | $202.74 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $178.34 | 2023-2025 | Onpattro, Amvuttra |
| Kestra Medical Technology Services, INC. | $142.59 | 2024-2025 | Assure Wcd |
| Lexicon Pharmaceuticals, INC. | $141.02 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $139.80 | 2019-2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $139.44 | 2022-2025 | (Ck4) Mcot, Extended Holter, Holter |
| Amarin Pharma, INC. | $115.23 | 2019-2023 | |
| Abbott Laboratories | $113.37 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Astellas Pharma US INC | $97.16 | 2019-2022 | |
| Edwards Lifesciences Corporation | $85.83 | 2019-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Esperion Therapeutics, INC. | $60.10 | 2023-2025 | Nexletol |
| Kiniksa Pharmaceuticals, Ltd. | $52.22 | 2023 | Arcalyst |
| Daiichi Sankyo INC. | $50.28 | 2019-2023 | Injectafer |
| Abiomed | $48.48 | 2019-2022 | |
| Ge Healthcare | $47.17 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.76 | 2021-2025 | |
| Inspire Medical Systems, INC. | $37.86 | 2024-2025 | Inspire |
| Atricure, INC. | $37.22 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Regeneron Healthcare Solutions, INC. | $33.85 | 2019-2025 | Evkeeza |
| Agepha Pharma Fz LLC | $32.48 | 2024 | Lodoco |
| Procyrion, INC. | $29.08 | 2024 | |
| Biogen, INC. | $28.33 | 2025 | Skyclarys |
| Scpharmaceuticals INC. | $23.32 | 2025 | |
| Irhythm Technologies, INC. | $22.91 | 2022 | |
| Glaxosmithkline, LLC. | $22.88 | 2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $21.52 | 2025 | Mounjaro |
| Vital Connect, INC | $21.34 | 2025 | Vitalpatch Rtm |
| Akcea Therapeutics, INC. | $18.58 | 2020 | |
| Watermark Medical, INC. | $18.40 | 2024 | |
| Bridgebio Pharma, INC. | $16.16 | 2025 | Attruby |
| Siemens Medical Solutions USA, INC. | $15.36 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Waldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.